



**Pannie (Panayiota) Trifillis, PhD, CAAM ([LinkedIn](#))**

Vice President, Global Medical Affairs  
Head of Global Scientific Affairs  
PTC Therapeutics, Inc.

*I am passionate about discovering, developing and commercializing first-in-class therapies for rare genetic disorders with a high unmet medical need, and providing access to treatment for every patient in need.*

I have been dedicated to this mission over the past 19 years. As the first scientist to join PTC Therapeutics, Inc.'s founding team at inception, I have been fortunate to have my contributions evolve to serve the needs of the company's growth milestones. I have been trusted to serve in diverse key functions in Research & Development, Strategic Alliance Management and Global Medical Affairs. My proudest contribution was shepherding a concept idea and taking an active role with the team to transform it into a first-approved drug product with global reach creating the potential for a multi-billion dollar market. Standing on the NASDAQ exchange floor witnessing the team's commitment over 15 years, culminating in PTC's IPO, was a humbling moment; and a reminder that the work of having our drug approved and made accessible globally to all patients in need was the next challenge to embrace.

As the first scientist at PTC, I initiated the program that led to the discovery and development of Translarna™, the first approved, disease-modifying treatment for nonsense mutation Duchenne Muscular Dystrophy (DMD), a fatal, orphan, rare genetic disease.



I subsequently led multiple drug discovery initiatives in diverse therapeutic areas beyond

genetic disorders including virology and oncology and collaborated with the Korean Research Institute of Bioscience and Biotechnology securing \$768,000 in grant funding to PTC.

I created aperture to market for the company by establishing and leading Alliance Management and executing on collaborative partnerships in diverse therapeutic areas including genetic disorders, oncology, central nervous system, cardiovascular and antibacterial diseases while working with partners in large pharma, biotech and non-profit organizations. Through these strategic joint discovery and development alliances with key partners, I delivered in excess of \$140M in revenues for PTC over 8 years.

As the company looked to increase global awareness among physicians and patient advocacy organizations in 2014, I shepherded a global outreach and advocacy campaign that led to the successful marketing authorization of Translarna™ by the European Medicines Agency in August of that year. This landmark approval has granted access to this breakthrough personalized medicine to patients in the European economic area and in certain world markets that recognize it. Currently, patients in Europe, the Middle East, East Asia, Latin America and Canada are receiving Translarna™. In 2017 PTC acquired Emflaza™, a disease-modifying drug that treats DMD that now patients in the US are able to receive.

As of 2017, I am VP, Global Medical Affairs and the Head of Global Scientific Affairs at PTC and I oversee the Publications, Medical Communications, Medical Information and Competencies Development teams. I am responsible for PTC's publication strategy and medical communications on DMD, Translarna™ and Emflaza™ ensuring that physicians around the world, our distribution partners and PTC's commercial team, are all well informed on the value propositions for both of our products.

I hold a PhD in Molecular Biology and Human Genetics from the University of Pennsylvania. I am an author of scientific publications and a patent holder, a speaker in the global arena, and a Fulbright Scholarship award recipient, fluent in English and Greek. I also hold a Certificate of Achievement in Alliance Management (CAAM) from the Association of Strategic Alliance Professionals.

Outside of work, I am a member of the Board of Directors and the Secretary of the Association of Greek American Professional Women (AGAPW), a charitable and educational organization established in New York City that seeks to expand career opportunities and promote community and leadership building among Greek-American professional women by forging collaborations among ourselves and establishing partnerships with other organizations.

I also serve as a mentor for AllilonNet, a non-profit organization of Greeks and friends of Greece with the goal to facilitate communication, networking, exchange of useful information and ideas, promoting a spirit of cooperation and solidarity in the fields of studies, career and entrepreneurship.

Since March 2017, I serve as a pharmaceutical/biotech industry reviewer on TechAdvance™, an early-stage technology funding program established by Rutgers University to advance Rutgers inventions and innovations towards commercialization.

I was born in Famagusta Cyprus. I am married and the mother of two children - high school and college students - and I live in NJ.